- Home
- NMM vs NUVB Comparison
NMM vs NUVB Comparison
Compare NMM & NUVB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NMM
- NUVB
- Stock Information
- Founded
- NMM 2007
- NUVB 2018
- Country
- NMM Greece
- NUVB United States
- Employees
- NMM N/A
- NUVB N/A
- Industry
- NMM Marine Transportation
- NUVB Biotechnology: Pharmaceutical Preparations
- Sector
- NMM Consumer Discretionary
- NUVB Health Care
- Exchange
- NMM Nasdaq
- NUVB Nasdaq
- Market Cap
- NMM 1.3B
- NUVB 1.1B
- IPO Year
- NMM 2007
- NUVB N/A
- Fundamental
- Price
- NMM $47.21
- NUVB $5.26
- Analyst Decision
- NMM
- NUVB Strong Buy
- Analyst Count
- NMM 0
- NUVB 7
- Target Price
- NMM N/A
- NUVB $8.43
- AVG Volume (30 Days)
- NMM 96.8K
- NUVB 8.2M
- Earning Date
- NMM 11-04-2025
- NUVB 11-03-2025
- Dividend Yield
- NMM 0.42%
- NUVB N/A
- EPS Growth
- NMM N/A
- NUVB N/A
- EPS
- NMM 10.24
- NUVB N/A
- Revenue
- NMM $1,305,026,000.00
- NUVB $14,355,000.00
- Revenue This Year
- NMM N/A
- NUVB $283.91
- Revenue Next Year
- NMM $9.93
- NUVB $340.13
- P/E Ratio
- NMM $4.61
- NUVB N/A
- Revenue Growth
- NMM N/A
- NUVB 900.35
- 52 Week Low
- NMM $28.37
- NUVB $1.54
- 52 Week High
- NMM $56.70
- NUVB $5.55
- Technical
- Relative Strength Index (RSI)
- NMM 58.60
- NUVB 76.37
- Support Level
- NMM $45.66
- NUVB $3.36
- Resistance Level
- NMM $47.10
- NUVB $3.84
- Average True Range (ATR)
- NMM 1.22
- NUVB 0.32
- MACD
- NMM 0.29
- NUVB 0.15
- Stochastic Oscillator
- NMM 88.77
- NUVB 86.76
About NMM Navios Maritime Partners LP Common Units Representing Limited Partner Interests
Navios Maritime Partners LP is a seaborne shipping company. It owns and operates dry cargo and container vessels with the primary long-term and staggered expiration charters. The firm's fleet consists of Ultra- Handymax, Panamax, Capsize, and Container vessels and categorized in Drybulk and Container vessels. It earns revenue through the chartering of vessels and voyage contracts. Geographically, it generates majority revenue from Asia.
About NUVB Nuvation Bio Inc.
Nuvation Bio Inc is a biopharmaceutical company tackling unmet needs in oncology by developing differentiated and novel therapeutic candidates. Its product candidate, taletrectinib, is an oral, potent, central nervous system-active, selective, next-generation c-ros oncogene 1 (ROS1) inhibitor specifically designed for the treatment of patients with ROS1+ non-small cell lung cancer (NSCLC). In addition, its clinical-stage pipeline includes differentiated, novel oncology product candidates such as Safusidenib, NUV-1511, and NUV-868 in their different stages of development. The company generates revenue through out-licensing collaborative agreements with its customers located in China and Japan.